Lycium para Mitigación de la atrofia muscular esquelética
Lycium barbarum — 5 estudios científicos revisados
Preliminary¿Sirve Lycium para mitigación de la atrofia muscular esquelética?
Mediante la activación de la vía de señalización AMPK/PINK1/Parkin, la cual promueve la mitofagia (eliminación de mitocondrias dañadas) para mejorar la función y estructura mitocondrial en el músculo.
Compuestos activos involucrados: Betaina, Flavonoides, Polisacárido, Vitamina c, Zeaxantina, ácido ascórbico, Beta-sitosterol, Carotenoides, Compuestos fenólicos, Sitosterol
Evidencia Científica
Los siguientes estudios han investigado la relación entre Lycium y mitigación de la atrofia muscular esquelética:
Effect of Lycium barbarum polysaccharides on cell signal transduction pathways.
Lycium barbarum polysaccharide (LBP), is a major active ingredient Lycium barbarum (LB), which exhibits several beneficial effects through NF-κB, PI3K-Akt-mTOR, p38-MAPK, Wnt-β-catenin, PI3K-Akt-GSK-3β, and MyD88 signal pathway, including anti-oxidation, and anti-aging, hypolipidemic and hypoglycemic, radiation, anti-tumor, and neuroprotection. Today, many researching papers are published on the LBP in physiology and pathology; however, the review of the LBP taking part in the signal transduction pathway in physiology and pathology is rear searched. Therefore, this research topic is a collecti
PubMed: 35032768Lycium barbarum glycopeptide promotes neuroprotection in ET-1 mediated retinal ganglion cell degeneration.
BACKGROUND: Vascular dysregulation is one of the major risk factors of glaucoma, and endothelin-1 (ET-1) may have a role in the pathogenesis of vascular-related glaucoma. Fruit extract from Lycium Barbarum (LB) exhibits anti-ageing and multitarget mechanisms in protecting retinal ganglion cells (RGC) in various animal models. To investigate the therapeutic efficacy of LB glycoproteins (LbGP) in ET-1 induced RGC degeneration, LbGP was applied under pre- and posttreatment conditions to an ET-1 mouse model. Retina structural and functional outcomes were characterised using clinical-based techniqu
PubMed: 39103918Lycium barbarum polysaccharides in ageing and its potential use for prevention and treatment of osteoarthritis: a systematic review.
BACKGROUND: Lycium barbarum polysaccharide (LBP), the most abundant functional component of wolfberry, is considered a potent antioxidant and an anti-ageing substance. This review aims to outline the hallmarks of ageing in the pathogenesis of osteoarthritis (OA), followed by the current understanding of the senolytic effect of LBP and its potential use in the prevention and treatment of OA. This will be discussed through the lens of molecular biology and herbal medicine. METHODS: A literature search was performed from inception to March 2020 using following keywords: "Lycium barbarum polysacch
PubMed: 34404395Lycium barbarum glycopeptide ameliorates motor and visual deficits in autoimmune inflammatory diseases.
BACKGROUND: Lycium barbarum glycopeptide (LbGp), extracted from the traditional Chinese medicine (TCM) of Lycium barbarum (LB), provides a neuroprotective effect against neurodegenerative and neuroimmune disorders contributing to its immunomodulatory and anti-inflammatory roles. Neuromyelitis optica spectrum disorders (NMOSD) is an autoimmune-mediated central nervous system (CNS) demyelinating disease, clinically manifested as transverse myelitis (TM) and optic neuritis. However, no drug has been demonstrated to be effective in relieving limb weakness and visual impairment of NMOSD patients. P
PubMed: 38640861Lycium barbarum (Wolfberry) glycopeptide prevents stress-induced anxiety disorders by regulating oxidative stress and ferroptosis in the medial prefrontal cortex.
BACKGROUND: Lycium barbarum (Wolfberry) extract has been shown to be effective in neuroprotection against aging or neural injury. Knowledge of its potential roles and biological mechanisms in relieving mental disorders, however, remains limited. PURPOSE: To investigate the potency of Lycium barbarum glycopeptide (LbGp) in alleviating anxiety disorders and the related biological mechanisms. METHODS: LbGp was administrated to mice subjected to 14 days of chronic restrain stress (CRS) via the intragastric route. The anxiolytic effect was evaluated by a battery of behavioral assays.
PubMed: 37182278Seguridad y Precauciones
En relación con el embarazo y la lactancia, no existen estudios clínicos exhaustivos en humanos que determinen la seguridad absoluta del consumo de Lycium barbarum en estas etapas. Debido a que los polisacáridos de Lycium barbarum (LBP) poseen una actividad inmunomoduladora y pueden influir en procesos de señalización celular complejos, se recomienda evitar su uso terapéutico durante la gestación para prevenir cualquier riesgo potencial de interferencia con el desarrollo fetal. En el periodo de lactancia, la falta de datos sobre la transferencia de compuestos bioactivos a través de la leche materna obliga a mantener una postura de precaución, sugiriءndo evitar su consumo para no exponer al lactante a dosis no controladas de compuestos con actividad farmacológica. Para niños menores de 12 años, la seguridad no ha sido establecida. Los sistemas metabólicos y de maduración inmunológica en la infancia son altamente sensibles; dado que el Lycium barbarum puede afectar las vías de señalización como NF-κB y PI3K-Akt, su uso en pediatría debe ser evitado a menos que exista una supervisión médica estricta. No se ha establecido una dosis máxima segura para la población pediátrica en la literatura científica proporcionada.
Perfil completo: Ver todos los usos y evidencia de Lycium →